3,680 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Everence Capital Management Inc.

Everence Capital Management Inc. bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,680 shares of the company’s stock, valued at approximately $301,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Riverview Trust Co acquired a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $27,000. Blue Trust Inc. boosted its stake in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Quest Partners LLC acquired a new stake in Vaxcyte in the second quarter worth $70,000. Meeder Asset Management Inc. increased its stake in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new position in shares of Vaxcyte during the third quarter valued at about $92,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Price Performance

NASDAQ PCVX opened at $87.29 on Wednesday. The company has a fifty day moving average price of $91.73 and a 200-day moving average price of $93.40. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of -18.98 and a beta of 0.98. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company earned ($0.91) earnings per share. On average, research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Finally, Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $145.71.

Insider Activity at Vaxcyte

In other news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,429,294.37. The trade was a 31.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares of the company’s stock, valued at approximately $17,208,443.70. The trade was a 3.74 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 113,732 shares of company stock valued at $11,730,787. 3.10% of the stock is owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.